Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (GlobeNewswire) - Mar 5, 2024 - "In 2024 the Company plans to accomplish the following key business objectives: 2024 FDA meeting to align on the design for a pivotal Phase 2/3 ReSPECT-LM trial for the treatment of breast cancer with leptomeningeal metastases, anticipated to begin in 1H 2025; Develop a new, multiple dosing ReSPECT-LM clinical trial in 2024; Complete preclinical combination studies of rhenium (186Re) obisbemeda with PD-1 and PD-L1 checkpoint inhibitors."
FDA event • New P2/3 trial • New trial • Preclinical • Brain Cancer • CNS Tumor • Oncology • Solid Tumor
|